%PDF-1.4
%
74 0 obj
<>
endobj
71 0 obj
<>
endobj
129 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2004-12-09T10:38:01Z
2024-03-28T01:42:17-07:00
QuarkXPressª: AdobePS 8.6 (219)
2024-03-28T01:42:17-07:00
application/pdf
Heather
2001-351.june02
uuid:b9ebd514-1dd1-11b2-0a00-8b08277d8900
uuid:b9ebd517-1dd1-11b2-0a00-d30000000000
endstream
endobj
60 0 obj
<>
endobj
61 0 obj
<>
endobj
75 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
1 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Type/Page>>
endobj
14 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Type/Page>>
endobj
27 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Type/Page>>
endobj
40 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
43 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
151 0 obj
[155 0 R]
endobj
152 0 obj
<>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
-1 793 614 -794 re
W n
q
0 792.06 612 -792 re
W n
BT
/CS0 cs 0 0 0 1 scn
/GS1 gs
/TT0 1 Tf
-0.00011 Tc 0.02499 Tw 8 0 0 8 61 714.5293 Tm
[(9.)-875.1 (Mehrian R, Quismorio FP)-238.2 (Jr)39.7 (, Strassmann G, et al. Syner)17.7 (gistic ef)17.7 (fect)]TJ
0 Tc 1.675 -1.25 Td
(between IL-10 and bcl-2 genotypes in determining susceptibility to)Tj
0 -1.25 TD
[(systemic lupus erythematosus. )54.8 (Arthritis Rheum 1998;41:596-602.)]TJ
-2.175 -1.25 Td
[(10.)-875 (Y)100.1 (asutomo K, Horiuchi )17.7 (T)74 (, Kagami S, et al. Mutation of DNASE1 in)]TJ
2.175 -1.25 Td
(people with systemic lupus erythematosus. Nat Genet 2001;)Tj
0 Tw T*
(28:313-4.)Tj
-0.00011 Tc 0.02499 Tw -2.1381 -1.25 Td
[(1)36.8 (1)-0.1 (.)-875.1 (Herrmann M, )17.7 (V)129.1 (oll RE, Zoller OM, Hagenhofer M, Ponner BB,)]TJ
0 Tc 2.1381 -1.25 Td
(Kalden JR. Impaired phagocytosis of apoptotic cell material by)Tj
T*
(monocyte-derived macrophages from patients with systemic lupus)Tj
T*
[(erythematosus. )54.9 (Arthritis Rheum 1998;41:1241-50.)]TJ
-2.175 -1.25 Td
[(12.)-875 (Botto M, Dell\222Agnola C, Bygrave )54.9 (AE, et al. Homozygous C1q)]TJ
2.175 -1.25 Td
(deficiency causes glomerulonephritis associated with multiple)Tj
T*
(apoptotic bodies. Nat Genet 1998;19:3-4 .)Tj
-0.00011 Tc -2.175 -1.25 Td
[(13.)-875.1 (Courtney P)91.7 (A, Crockard )54.8 (AD, )17.7 (W)39.7 (illiamson K, Irvine )54.8 (AE, Kennedy RJ,)]TJ
0 Tc 2.175 -1.25 Td
[(Bell )54.9 (AL. Increased apoptotic peripheral blood neutrophils in)]TJ
T*
[(systemic lupus erythematosus: relations with disease activity)64.9 (,)]TJ
T*
[(antibodies to double stranded DNA, and neutropenia. )54.9 (Ann Rheum)]TJ
T*
(Dis 1999;58:309-14.)Tj
-2.175 -1.25 Td
[(14.)-875 (Caricchio R, Cohen PL. Spontaneous and induced apoptosis in)]TJ
2.175 -1.25 Td
(systemic lupus erythematosus: multiple assays fail to reveal)Tj
T*
(consistent abnormalities. Cell Immunol 1999;198:54-60.)Tj
-2.175 -1.25 Td
[(15.)-875 (Courtney P)91.8 (A, Crockard )54.8 (AD, )17.7 (W)39.8 (illiamson K, McConnell J, Kennedy)]TJ
2.175 -1.25 Td
[(RJ, Bell )54.8 (AL. L)54.9 (ymphocyte apoptosis in systemic lupus erythe-)]TJ
-0.00011 Tc T*
(matosus: relationships with Fas expression, serum soluble Fas and)Tj
0 Tc T*
[(disease activity)64.9 (. Lupus 1999;8:508-13.)]TJ
-2.175 -1.25 Td
[(16.)-875 (Emlen )17.7 (W)91.8 (,)0.1 ( Niebur JA, Kadera R. )54.8 (Accelerated in vitro apoptosis of)]TJ
2.175 -1.25 Td
(lymphocytes from patients with systemic lupus erythematosus. )Tj
T*
(J Immunol 1994;152:3685-92.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(17.)-875.1 (McNally J, )36.8 (Y)100 (o)-0.1 (o DH, Drappa J, et al. Fas ligand expression and)]TJ
0 Tc 2.175 -1.25 Td
(function in systemic lupus erythematosus. J Immunol)Tj
0 Tw T*
(1997;159:4628-36.)Tj
0.02499 Tw -2.175 -1.25 Td
[(18.)-875 (Rumore PM, Steinman CR. Endogenous circulating DNA)-220.1 (in)]TJ
2.175 -1.25 Td
(systemic lupus erythematosus: occurrence as multimeric complexes)Tj
T*
(bound to histone. J Clin Invest 1990;86:69-74.)Tj
-2.175 -1.25 Td
[(19.)-875 (Utz PJ, )54.8 (Anderson P)110.8 (. Posttranslational protein modifications,)]TJ
2.175 -1.25 Td
[(apoptosis, and the bypass of tolerance to autoantigens. )54.9 (Arthritis)]TJ
T*
[(Rheum 1998;41:1)36.9 (152-60.)]TJ
-2.175 -1.25 Td
[(20.)-875 (Mevorach D, Zhou JL, Song X, Elkon KB. Systemic exposure to)]TJ
2.175 -1.25 Td
(irradiated apoptotic cells induces autoantibody production. J Exp)Tj
T*
(Med 1998;188:387-92.)Tj
-2.175 -1.25 Td
[(21.)-875 (Mysler E, Bini P)110.8 (, Drappa J, et al. )17.7 (The apoptosis-1/ Fas protein in)]TJ
2.175 -1.25 Td
(human systemic lupus erythematosus. J Clin Invest 1994;)Tj
0 Tw T*
(93:1029-34.)Tj
-0.00011 Tc 0.02499 Tw 30.825 52.5 Td
[(22.)-875.1 (Ohsako S, Hara M, Harigai M, Fukasawa C, Kashiwazaki S.)]TJ
0 Tc 2.175 -1.25 Td
(Expression and function of Fas antigen and bcl-2 in human)Tj
T*
(systemic lupus erythematosus lymphocytes. Clin Immunol)Tj
T*
(Immunopathol 1994;73:109-14.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(23.)-875.1 (Huang QR, Morris D, Manolios N. Identification and)]TJ
0 Tc 2.175 -1.25 Td
(characterization of polymorphisms in the promoter region of the)Tj
T*
[(human )54.9 (Apo-1/Fas \(CD95\) gene. Mol Immunol 1997;34:577-82.)]TJ
-2.175 -1.25 Td
[(24.)-875 (T)69.8 (an EM, Cohen )54.8 (AS, Fries JF)79.8 (, et al. )17.7 (The 1982 revised criteria for the)]TJ
-0.00011 Tc 2.175 -1.25 Td
[(classification of systemic lupus erythematosus. )54.8 (Arthritis Rheum)]TJ
0 Tc 0 Tw T*
(1982;25:1271-7.)Tj
0.02499 Tw -2.175 -1.25 Td
[(25.)-875 (Lewontin RC. )17.8 (The interaction of selection and linkage. I. General)]TJ
2.175 -1.25 Td
(considerations; heterotic models. Genetics 1964;49:49-67.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(26.)-875.1 (Rudert F)79.7 (,)-0.1 ( )17.7 (V)60 (isser E, Forbes L, Lindridge E, )17.7 (W)79.7 (ang )36.8 (Y)129 (,)-0.1 ( )17.7 (W)79.7 (atson J.)]TJ
0 Tc 2.175 -1.25 Td
[(Identification of a silencer)39.8 (, enhancer)39.8 (, and basal promoter region in)]TJ
-0.00011 Tc T*
[(the human CD95 \(Fas/Apo-1\) gene. DNA)-220.2 (Cell Biol 1995;14:931-7.)]TJ
0 Tc -2.175 -1.25 Td
[(27.)-875 (Cascino I, Ballerini C, )54.9 (Audino S, et al. Fas gene polymorphisms are)]TJ
2.175 -1.25 Td
(not associated with systemic lupus erythematosus, multiple)Tj
-0.00011 Tc T*
[(sclerosis and HIV)-257.3 (infection. Dis Markers 1998;13:221-5.)]TJ
-2.175 -1.25 Td
[(28.)-875.1 (Huang QR, Danis )17.7 (V)129.1 (, Lassere M, Edmonds J, Manolios N.)]TJ
2.175 -1.25 Td
[(Evaluation of a new )54.8 (Apo-1/Fas promoter polymorphism in)]TJ
0 Tc T*
(rheumatoid arthritis and systemic lupus erythematosus patients.)Tj
T*
(Rheumatol 1999;38:645-51.)Tj
-2.175 -1.25 Td
[(29.)-875 (Huang QR, Manolios N. Investigation of the -1377 polymorphism)]TJ
-0.00011 Tc 2.175 -1.25 Td
[(on the )54.8 (Apo-1/Fas promoter in systemic lupus erythematosus)]TJ
0 Tc T*
(patients using allele-specific amplification. Pathology 2000;)Tj
0 Tw T*
(32:126-30.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(30.)-875.1 (Rudert F)79.7 (,)-0.1 ( Lindridge E, Lasham )54.8 (A, )17.7 (W)79.7 (ang )36.8 (Y)129.1 (, Grandison P)110.7 (,)-0.1 ( )17.7 (W)79.7 (atson J.)]TJ
0 Tc 2.175 -1.25 Td
(Silencer and enhancer regions in the human CD95 \(Fas/Apo-1\))Tj
T*
(gene with sequence similarity to the granulocyte-macrophage)Tj
T*
(colony-stimulating factor promoter: binding of single strand-)Tj
-0.00011 Tc T*
[(specific silencer factors and )54.8 (AP-1 and NF-A)110.7 (T)91.7 (-like enhancer factors.)]TJ
0 Tc T*
[(DNA)-220.1 (Cell Biol 1998;17:991-1002.)]TJ
-0.00011 Tc -2.175 -1.25 Td
[(31.)-875.1 (Chan H, Bartos DP)110.7 (, Owen-Schaub LB. )54.8 (Activation-dependent)]TJ
2.175 -1.25 Td
(transcriptional regulation of the human fas promoter requires NF-)Tj
0 Tc T*
(kB p50-p65 recruitment. Mol Cell Biol 1999;19:2098-108.)Tj
-2.175 -1.25 Td
[(32.)-875 (Lasham )54.8 (A, Lindridge E, Rudert F)79.8 (,)0.1 ( Onrust R, )17.7 (W)79.8 (atson J. Regulation)]TJ
-0.00011 Tc 2.175 -1.25 Td
[(of the human fas promoter by )36.8 (YB-1, Pur\337 and )54.8 (AP-1 transcription)]TJ
0 Tc T*
(factors. Gene 2000;252:1-13. )Tj
-0.00011 Tc -2.175 -1.25 Td
[(33.)-875.1 (Rudert F)79.7 (,)-0.1 ( )17.7 (V)60 (isser E, Forbes L, Lindridge E, )17.7 (W)79.7 (ang )36.8 (Y)129 (,)-0.1 ( )17.7 (W)79.7 (atson J.)]TJ
0 Tc 2.175 -1.25 Td
[(Identification of a silencer)39.8 (, enhancer)39.8 (, and basal promoter region in)]TJ
-0.00011 Tc T*
[(the human CD95 \(Fas/Apo-1\) gene. DNA)-220.2 (Cell Biol 1995;14:931-7.)]TJ
ET
/CS0 CS 0 0 0 1 SCN
54 54 m
558 54 l
S
BT
/TT1 1 Tf
0 Tc 8 0 0 8 424.3613 35.9844 Tm
(The Journal of Rheumatology 2002; 29:6)Tj
0 Tw -46.2952 -0.0313 Td
(1188)Tj
ET
0 0 0 0 scn
/GS0 gs
102.94 59.08 407.5 -10.83 re
f*
0.5 w
102.94 59.08 407.5 -10.83 re
S
Q
Q
q
0 0 612 792 re
W n
BT
0 g
/GS2 gs
/T1_0 8 Tf
120.092 51 Td
(Personal non-commercial use only. The Journal of Rheumatology Copyright\
\251 2002. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_1 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-16.72996 0 Td
(Downloaded on March 28, 2024 from )Tj
ET
endstream
endobj
116 0 obj
<>
endobj
134 0 obj
<>
endobj
83 0 obj
<>
endobj
77 0 obj
<>
endobj
79 0 obj
<>
endobj
111 0 obj
<>stream
HV pUBBzI$c!\$CpH"9HT)PQ*,["դ-
E`A(9@b!$\Zx3 ڡ
ƾӷn3Ԏ)Wb KkS;
Q9iFp$ 9㕅UbkW6qO Q" K]:'zj+sJTw
~rTAUd||鯿,ߴM=PK>̯nт϶W+לLZgVMR$:K\%nJP/%Њux ~g>h;$6b9n#-.zQ_OG.}XixNqXkyE%kHxKbՌ)6ˉ6a9'5HYx284;vo㮎
b{VaY1UV+VE~j wDmu6[MAwUѐ.3#w
f`
6238qWD(L/Sҫ.5FbA
+, ~Hޓ1
~B=9^m "Ol9Y!{UQWka&p}|Fqn!HFk;n}8\@3ЄSDn"_$3⼌qҐ%SQO5ohMG*Z3<ܮ˘Je̽^c)
|_c8s<:nC3nYDX&ܬv@5bKśb
9~(vaV2_)r\!')*oȟH%UqƇ|DݡEkӴEZPФPM崢Zlm@{`G2QQ6Q
foYύpvO.fv's~=<@H@s"sɌQ(d1UL" "渒cxYn;E/[6۫(A2ɗ~ރJH.*,M[a5!)8(eW*k-VeҬW(j:V]SruвZV^Ղ{ZK;suN9sswOړ=وOQE\g|vzOP >)?r8̛5b'H z>װ.|ZB-:tfYi=OQ\U#?)y Oݳwgef!}tm"#MU@t#FmSB3u?c꾰xzy}tGQ+zuQZM(\ܡ{y)|^z}y4mYh7Dq 5